Chemicals - Specialty
Compare Stocks
5 / 10Stock Comparison
SXT vs IFF vs BCPC vs AVNT vs IOSP
Revenue, margins, valuation, and 5-year total return — side by side.
Chemicals - Specialty
Chemicals - Specialty
Chemicals - Specialty
Chemicals - Specialty
SXT vs IFF vs BCPC vs AVNT vs IOSP — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Chemicals - Specialty | Chemicals - Specialty | Chemicals - Specialty | Chemicals - Specialty | Chemicals - Specialty |
| Market Cap | $5.01B | $19.99B | $5.11B | $3.35B | $1.91B |
| Revenue (TTM) | $1.61B | $10.79B | $1.06B | $3.28B | $1.78B |
| Net Income (TTM) | $134M | $839M | $158M | $158M | $117M |
| Gross Margin | 33.5% | 35.1% | 36.3% | 31.7% | 27.7% |
| Operating Margin | 12.8% | 8.0% | 21.0% | 9.3% | 8.7% |
| Forward P/E | 31.1x | 17.8x | 30.9x | 12.0x | 15.5x |
| Total Debt | $779M | $6.65B | $192M | $1.92B | $90M |
| Cash & Equiv. | $37M | $590M | $75M | $511M | $293M |
SXT vs IFF vs BCPC vs AVNT vs IOSP — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Sensient Technologi… (SXT) | 100 | 235.1 | +135.1% |
| International Flavo… (IFF) | 100 | 58.8 | -41.2% |
| Balchem Corporation (BCPC) | 100 | 158.5 | +58.5% |
| Avient Corporation (AVNT) | 100 | 147.3 | +47.3% |
| Innospec Inc. (IOSP) | 100 | 99.4 | -0.6% |
Price return only. Dividends and distributions are not included.
Quick Verdict: SXT vs IFF vs BCPC vs AVNT vs IOSP
Each card shows where this stock fits in a portfolio — not just who wins on paper.
SXT ranks third and is worth considering specifically for defensive.
- Beta 0.63, yield 1.4%, current ratio 4.10x
- +26.7% vs IOSP's -14.9%
IFF lags the leaders in this set but could rank higher in a more targeted comparison.
BCPC carries the broadest edge in this set and is the clearest fit for growth exposure and long-term compounding.
- Rev growth 8.8%, EPS growth 20.9%, 3Y rev CAGR 3.2%
- 160.5% 10Y total return vs SXT's 101.6%
- Lower volatility, beta 0.33, Low D/E 15.3%, current ratio 2.07x
- 8.8% revenue growth vs IFF's -5.2%
AVNT is the #2 pick in this set and the best alternative if income & stability is your priority.
- Dividend streak 14 yrs, beta 1.19, yield 2.9%
- Lower P/E (12.0x vs 30.9x)
- 2.9% yield, 14-year raise streak, vs BCPC's 0.5%
IOSP is the clearest fit if your priority is valuation efficiency.
- PEG 0.48 vs SXT's 7.65
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 8.8% revenue growth vs IFF's -5.2% | |
| Value | Lower P/E (12.0x vs 30.9x) | |
| Quality / Margins | 15.0% margin vs AVNT's 4.8% | |
| Stability / Safety | Beta 0.33 vs AVNT's 1.19, lower leverage | |
| Dividends | 2.9% yield, 14-year raise streak, vs BCPC's 0.5% | |
| Momentum (1Y) | +26.7% vs IOSP's -14.9% | |
| Efficiency (ROA) | 9.4% ROA vs AVNT's 2.6%, ROIC 12.2% vs 3.9% |
SXT vs IFF vs BCPC vs AVNT vs IOSP — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
SXT vs IFF vs BCPC vs AVNT vs IOSP — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
BCPC leads in 2 of 6 categories
AVNT leads 2 • SXT leads 1 • IFF leads 0 • IOSP leads 0 • 1 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
BCPC leads this category, winning 5 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
IFF is the larger business by revenue, generating $10.8B annually — 10.2x BCPC's $1.1B. BCPC is the more profitable business, keeping 15.0% of every revenue dollar as net income compared to AVNT's 4.8%. On growth, BCPC holds the edge at +8.1% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $1.6B | $10.8B | $1.1B | $3.3B | $1.8B |
| EBITDAEarnings before interest/tax | $268M | $1.7B | $267M | $445M | $198M |
| Net IncomeAfter-tax profit | $134M | $839M | $158M | $158M | $117M |
| Free Cash FlowCash after capex | $38M | $400M | $182M | $205M | $88M |
| Gross MarginGross profit ÷ Revenue | +33.5% | +35.1% | +36.3% | +31.7% | +27.7% |
| Operating MarginEBIT ÷ Revenue | +12.8% | +8.0% | +21.0% | +9.3% | +8.7% |
| Net MarginNet income ÷ Revenue | +8.3% | +7.8% | +15.0% | +4.8% | +6.6% |
| FCF MarginFCF ÷ Revenue | +2.4% | +3.7% | +17.2% | +6.3% | +4.9% |
| Rev. Growth (YoY)Latest quarter vs prior year | +4.5% | -3.6% | +8.1% | +2.5% | -2.4% |
| EPS Growth (YoY)Latest quarter vs prior year | -15.5% | +116.6% | +10.6% | +3.8% | +167.7% |
Valuation Metrics
AVNT leads this category, winning 4 of 7 comparable metrics.
Valuation Metrics
At 16.4x trailing earnings, IOSP trades at a 60% valuation discount to AVNT's 41.0x P/E. Adjusting for growth (PEG ratio), IOSP offers better value at 0.51x vs SXT's 9.19x — a lower PEG means you pay less per unit of expected earnings growth.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $5.0B | $20.0B | $5.1B | $3.3B | $1.9B |
| Enterprise ValueMkt cap + debt − cash | $5.8B | $26.1B | $5.2B | $4.8B | $1.7B |
| Trailing P/EPrice ÷ TTM EPS | 37.29x | -53.60x | 33.58x | 41.01x | 16.41x |
| Forward P/EPrice ÷ next-FY EPS est. | 31.06x | 17.84x | 30.87x | 11.95x | 15.45x |
| PEG RatioP/E ÷ EPS growth rate | 9.19x | — | 2.62x | — | 0.51x |
| EV / EBITDAEnterprise value multiple | 21.46x | 13.28x | 19.83x | 12.22x | 8.29x |
| Price / SalesMarket cap ÷ Revenue | 3.11x | 1.84x | 4.92x | 1.03x | 1.07x |
| Price / BookPrice ÷ Book value/share | 4.21x | 1.41x | 4.14x | 1.40x | 1.44x |
| Price / FCFMarket cap ÷ FCF | 130.53x | 78.09x | 29.51x | 17.16x | 21.68x |
Profitability & Efficiency
BCPC leads this category, winning 6 of 9 comparable metrics.
Profitability & Efficiency
BCPC delivers a 12.4% return on equity — every $100 of shareholder capital generates $12 in annual profit, vs $6 for IFF. IOSP carries lower financial leverage with a 0.07x debt-to-equity ratio, signaling a more conservative balance sheet compared to AVNT's 0.81x. On the Piotroski fundamental quality scale (0–9), BCPC scores 9/9 vs AVNT's 5/9, reflecting strong financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | +11.6% | +5.9% | +12.4% | +6.6% | +9.0% |
| ROA (TTM)Return on assets | +6.1% | +3.3% | +9.4% | +2.6% | +6.5% |
| ROICReturn on invested capital | +8.6% | +3.5% | +12.2% | +3.9% | +11.2% |
| ROCEReturn on capital employed | +11.1% | +4.4% | +14.8% | +4.0% | +11.0% |
| Piotroski ScoreFundamental quality 0–9 | 5 | 5 | 9 | 5 | 6 |
| Debt / EquityFinancial leverage | 0.65x | 0.47x | 0.15x | 0.81x | 0.07x |
| Net DebtTotal debt minus cash | $742M | $6.1B | $117M | $1.4B | -$203M |
| Cash & Equiv.Liquid assets | $37M | $590M | $75M | $511M | $293M |
| Total DebtShort + long-term debt | $779M | $6.7B | $192M | $1.9B | $90M |
| Interest CoverageEBIT ÷ Interest expense | 7.00x | 5.26x | 15.23x | 3.61x | — |
Total Returns (Dividends Reinvested)
SXT leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in SXT five years ago would be worth $14,807 today (with dividends reinvested), compared to $6,190 for IFF. Over the past 12 months, SXT leads with a +26.7% total return vs IOSP's -14.9%. The 3-year compound annual growth rate (CAGR) favors SXT at 17.3% vs IOSP's -6.1% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | +26.6% | +15.6% | +3.6% | +16.0% | +0.5% |
| 1-Year ReturnPast 12 months | +26.7% | +8.5% | -2.2% | +4.1% | -14.9% |
| 3-Year ReturnCumulative with dividends | +61.3% | -13.2% | +26.6% | +2.3% | -17.3% |
| 5-Year ReturnCumulative with dividends | +48.1% | -38.1% | +24.2% | -22.7% | -18.3% |
| 10-Year ReturnCumulative with dividends | +101.6% | -12.6% | +160.5% | +27.8% | +84.4% |
| CAGR (3Y)Annualised 3-year return | +17.3% | -4.6% | +8.2% | +0.8% | -6.1% |
Risk & Volatility
Evenly matched — IFF and BCPC each lead in 1 of 2 comparable metrics.
Risk & Volatility
BCPC is the less volatile stock with a 0.33 beta — it tends to amplify market swings less than AVNT's 1.19 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. IFF currently trades 93.0% from its 52-week high vs IOSP's 80.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.63x | 0.68x | 0.33x | 1.19x | 0.70x |
| 52-Week HighHighest price in past year | $129.35 | $84.19 | $183.90 | $44.85 | $95.55 |
| 52-Week LowLowest price in past year | $82.60 | $59.14 | $139.17 | $27.48 | $65.58 |
| % of 52W HighCurrent price vs 52-week peak | +91.1% | +93.0% | +86.7% | +81.4% | +80.2% |
| RSI (14)Momentum oscillator 0–100 | 67.8 | 72.5 | 32.9 | 55.2 | 59.1 |
| Avg Volume (50D)Average daily shares traded | 372K | 1.6M | 190K | 620K | 221K |
Analyst Outlook
AVNT leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Analyst consensus: SXT as "Buy", IFF as "Buy", BCPC as "Buy", AVNT as "Buy", IOSP as "Hold". Consensus price targets imply 50.1% upside for IOSP (target: $115) vs 1.6% for BCPC (target: $162). For income investors, AVNT offers the higher dividend yield at 2.95% vs BCPC's 0.54%.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | Buy | Buy | Hold |
| Price TargetConsensus 12-month target | $143.00 | $87.75 | $162.00 | $48.40 | $115.00 |
| # AnalystsCovering analysts | 12 | 33 | 10 | 20 | 9 |
| Dividend YieldAnnual dividend ÷ price | +1.4% | +2.0% | +0.5% | +2.9% | +2.2% |
| Dividend StreakConsecutive years of raises | 1 | 0 | 11 | 14 | 12 |
| Dividend / ShareAnnual DPS | $1.63 | $1.60 | $0.87 | $1.08 | $1.70 |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +0.2% | +2.1% | +0.1% | 0.0% |
BCPC leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). AVNT leads in 2 (Valuation Metrics, Analyst Outlook). 1 tied.
SXT vs IFF vs BCPC vs AVNT vs IOSP: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is SXT or IFF or BCPC or AVNT or IOSP a better buy right now?
For growth investors, Balchem Corporation (BCPC) is the stronger pick with 8.
8% revenue growth year-over-year, versus -5. 2% for International Flavors & Fragrances Inc. (IFF). Innospec Inc. (IOSP) offers the better valuation at 16. 4x trailing P/E (15. 5x forward), making it the more compelling value choice. Analysts rate Sensient Technologies Corporation (SXT) a "Buy" — based on 12 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — SXT or IFF or BCPC or AVNT or IOSP?
On trailing P/E, Innospec Inc.
(IOSP) is the cheapest at 16. 4x versus Avient Corporation at 41. 0x. On forward P/E, Avient Corporation is actually cheaper at 12. 0x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Innospec Inc. wins at 0. 48x versus Sensient Technologies Corporation's 7. 65x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.
03Which is the better long-term investment — SXT or IFF or BCPC or AVNT or IOSP?
Over the past 5 years, Sensient Technologies Corporation (SXT) delivered a total return of +48.
1%, compared to -38. 1% for International Flavors & Fragrances Inc. (IFF). Over 10 years, the gap is even starker: BCPC returned +160. 5% versus IFF's -12. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — SXT or IFF or BCPC or AVNT or IOSP?
By beta (market sensitivity over 5 years), Balchem Corporation (BCPC) is the lower-risk stock at 0.
33β versus Avient Corporation's 1. 19β — meaning AVNT is approximately 262% more volatile than BCPC relative to the S&P 500. On balance sheet safety, Innospec Inc. (IOSP) carries a lower debt/equity ratio of 7% versus 81% for Avient Corporation — giving it more financial flexibility in a downturn.
05Which is growing faster — SXT or IFF or BCPC or AVNT or IOSP?
By revenue growth (latest reported year), Balchem Corporation (BCPC) is pulling ahead at 8.
8% versus -5. 2% for International Flavors & Fragrances Inc. (IFF). On earnings-per-share growth, the picture is similar: Innospec Inc. grew EPS 228. 9% year-over-year, compared to -253. 7% for International Flavors & Fragrances Inc.. Over a 3-year CAGR, SXT leads at 3. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — SXT or IFF or BCPC or AVNT or IOSP?
Balchem Corporation (BCPC) is the more profitable company, earning 14.
9% net margin versus -3. 4% for International Flavors & Fragrances Inc. — meaning it keeps 14. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: BCPC leads at 21. 1% versus 6. 2% for AVNT. At the gross margin level — before operating expenses — BCPC leads at 35. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is SXT or IFF or BCPC or AVNT or IOSP more undervalued right now?
The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.
By this metric, Innospec Inc. (IOSP) is the more undervalued stock at a PEG of 0. 48x versus Sensient Technologies Corporation's 7. 65x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Avient Corporation (AVNT) trades at 12. 0x forward P/E versus 31. 1x for Sensient Technologies Corporation — 19. 1x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for IOSP: 50. 1% to $115. 00.
08Which pays a better dividend — SXT or IFF or BCPC or AVNT or IOSP?
All stocks in this comparison pay dividends.
Avient Corporation (AVNT) offers the highest yield at 2. 9%, versus 0. 5% for Balchem Corporation (BCPC).
09Is SXT or IFF or BCPC or AVNT or IOSP better for a retirement portfolio?
For long-horizon retirement investors, Balchem Corporation (BCPC) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.
33), 0. 5% yield, +160. 5% 10Y return). Both have compounded well over 10 years (BCPC: +160. 5%, AVNT: +27. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between SXT and IFF and BCPC and AVNT and IOSP?
Both stocks operate in the Basic Materials sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: SXT is a small-cap quality compounder stock; IFF is a mid-cap quality compounder stock; BCPC is a small-cap quality compounder stock; AVNT is a small-cap quality compounder stock; IOSP is a small-cap deep-value stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.